Latest Stocks: FY2019 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)

Latest Stocks: FY2019 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)

CYTX has been the subject of several other reports. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 13th. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Cytori Therapeutics in a research note on Tuesday, January 24th. Cytori Therapeutics (NASDAQ:CYTX) traded down 0.0109% during trading on Monday, hitting $0.9199. The stock had a trading volume of 140,363 shares. The stock has a 50 day moving average price of $1.17 and a 200-day moving average price of $1.51. The stock’s market cap is $21.68 million. Cytori Therapeutics has a 12 month low of $0.90 and a 12 month high of $3.40.

Cytori Therapeutics Inc (NASDAQ:CYTX) – Equities research analysts at B. Riley dropped their FY2019 earnings per share estimates for Cytori Therapeutics in a research report issued on Friday. B. Riley analyst A. D’silva now anticipates that the biotechnology company will earn $0.15 per share for the year, down from their prior forecast of $0.16. B. Riley currently has a “Buy” rating and a $2.30 target price on the stock.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. raised its position in Cytori Therapeutics Inc (NASDAQ:CYTX) by 19.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 336,651 shares of the biotechnology company’s stock after buying an additional 55,948 shares during the period. Vanguard Group Inc. owned 1.43% of Cytori Therapeutics worth $539,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 14.17% of the company’s stock. About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Related posts

Leave a Comment